The aim of this study is to see if administering platelets (cells in our blood that stop or prevent bleeding) results in improved platelet function and slows/stops the progression of a head bleed for patients who have a traumatic head bleed and are on antiplatelet therapy (medications that stop blood cells from forming a blood clot) prior to admission.
This study aims to determine if platelet function has improved following platelet transfusion by prospectively performing repeat thromboelastographic with platelet mapping (TEG-PM) assays on all patients consented and enrolled in the study. This study will also examine the rate of progression or stability of ICH on repeat head CT following platelet administration and will aid in the determination of a potential association between repeat CT head findings and the repeat TEG-PM results.
Study Type
OBSERVATIONAL
Enrollment
225
Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.
Penn Medicine Lancaster General Health
Lancaster, Pennsylvania, United States
Repeat TEG
Rate of reversed pathway inhibition on repeat thromboelastography with platelet mapping (TEG-PM) when platelets are administered to TICH patients who are on antiplatelet therapy prior to admission.
Time frame: 1 hour after platelets given
Repeat Head CT
Number of patients with improved platelet function on repeat TEG-PM and stability of TICH on subsequent CT scan.
Time frame: From the time of interventional platelet administration until the time of patient discharge from their index admission, assessed up to 100 weeks.
Need for Neurosurgical Intervention
Determine the efficacy of platelet transfusion among this patient cohort by measuring need for neurosurgical intervention after second CT scan (ie: the failure of non-operative management)
Time frame: During index admission for traumatic intracranial hemorrhage (TICH), assessed through study completion, an average of 2 years.
Discharge Status
Determine the efficacy of platelet transfusion among this patient cohort by reviewing discharge status.
Time frame: From the time of interventional platelet administration until the time of patient discharge from their index admission assessed through study completion, an average of 2 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.